SRA-444 succinate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: SRA-444 succinate
• 英文别名: 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline trisuccinate；5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)-quinoline；5-fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl}quinoline tri-succinate；Butanedioic acid;5-fluoro-8-[4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl]quinoline
• 化学式: 3C₄H₆O₄*C₂₈H₃₀FN₅O
• 分子量: 825.845
• InChiKey: ASHSTBZAHLVOOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.66
• 重原子数：
  43
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  8-氨基-6-甲氧基喹啉 在 sodium hydroxide 、 水 、 三乙酰氧基硼氢化钠 作用下， 以 四氢呋喃 、 正庚烷 、 二氯甲烷 、 甲苯 、 正己醇 为溶剂， 反应 42.25h， 生成 SRA-444 succinate
  参考文献：
  名称：

  WO2007/146202

  摘要：

  公开号：

文献信息

• Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor
  申请人：Asselin Magda

  公开号：US20070027160A1

  公开（公告）日：2007-02-01

  The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT 1A binding agents, particularly as 5-HT 1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction.

  本发明涉及新型哌嗪-哌啶化合物。这些化合物可用作5-HT1A结合剂，特别是作为5-HT1A受体拮抗剂和激动剂。这些化合物在治疗中枢神经系统疾病方面很有用，如认知障碍、焦虑症、抑郁症和性功能障碍。
• WO2007/146072
  申请人：——

  公开号：——

  公开（公告）日：——
• Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution
  申请人：Ku Mannching Sherry

  公开号：US20080199518A1

  公开（公告）日：2008-08-21

  The present invention relates to controlled-release beads comprising diquinoline-substituted piperazine-piperidine compounds, such as 5-fluoro-8-4-[4-[(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl}quinoline, or pharmaceutically acceptable salts thereof; to multiple particulate formulations comprising such beads; to methods of preparing such beads; and to methods of treating 5-HT 1A -related disorders using such beads and/or multiple particulate formulations.
• SUSTAINED-RELEASE TABLET FORMULATIONS OF PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR HAVING ENHANCED INTESTINAL DISSOLUTION
  申请人：Wen Hong

  公开号：US20080226714A1

  公开（公告）日：2008-09-18

  The present invention relates to sustained-release tablet formulations of piperazine-piperidine compounds, which can be useful in treating central nervous system disorders; to processes for their preparation; and to methods of using them.
• [EN] SUSTAINED-RELEASE TABLET FORMULATIONS OF PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR HAVING ENHANCED INTESTINAL DISSOLUTION<br/>[FR] FORMULATIONS DE COMPRIMÉ À LIBÉRATION PROLONGÉE À BASE D'ANTAGONISTES ET D'AGONISTES DE PIPÉRAZINE-PIPÉRIDINE DU RÉCEPTEUR 5-HT1A, AYANT UNE DISSOLUTION INTESTINALE AMÉLIORÉE
  申请人：WYETH CORP

  公开号：WO2008101139A1

  公开（公告）日：2008-08-21

  [EN] The present invention relates to sustained-release tablet formulations of piperazine- piperidine compounds, which can be useful in treating central nervous system disorders; to processes for their preparation; and to methods of using them.
  [FR] L'invention concerne des formulations de comprimé à libération prolongée à base de composés de pipérazine-pipéridine pouvant être utiles dans le traitement de troubles du système nerveux central ; des procédés pour leur préparation ; et des procédés pour leur utilisation.